Growth hormone secretagogues vs. recombinant GH, what the published pharmacology actually shows

Key takeaways

• GH secretagogues fall into two pharmacological families: GHRH analogs (sermorelin, tesamorelin, CJC-1295) bind the GHRH receptor on pituitary somatotrophs, and ghrelin/GHS-R1a agonists (ipamorelin, MK-677, GHRP-2, GHRP-6, hexarelin, macimorelin) bind the growth hormone secretagogue receptor.
• Tesamorelin (Egrifta WR) is FDA-approved for HIV-associated lipodystrophy and demonstrably reduces visceral adipose tissue. Macimorelin (Macrilen) is FDA-approved as a diagnostic test for adult growth hormone deficiency.
• Sermorelin (originally marketed as Geref) was an FDA-approved injectable for pediatric short stature; the approved product was discontinued from the US market in the late 2000s for commercial reasons. Sermorelin in current US clinical use is compounded, not FDA-approved.
• MK-677 (ibutamoren) is an oral, orally available ghrelin-receptor agonist that has been studied in placebo-controlled trials for several years; the most consistent finding is increased fat-free mass and increased fasting blood glucose, with edema and insulin resistance as labeled-concern effects.
• WADA prohibits all growth hormone secretagogues at all times, the same posture as recombinant human growth hormone, in elite competitive athletes.

Two receptor families, different pharmacology

All GH secretagogues raise circulating growth hormone, but they do so through different receptors and with different downstream consequences. GHRH analogs (the natural growth hormone-releasing hormone, sermorelin, tesamorelin, CJC-1295) bind the GHRH receptor on pituitary somatotrophs and amplify the natural GHRH-driven GH pulse. The endogenous somatostatin brake remains, which preserves the pulsatile shape of GH release. GHRP family compounds (ipamorelin, GHRP-2, GHRP-6, hexarelin, MK-677) bind the growth hormone secretagogue receptor (GHS-R1a, the ghrelin receptor) and stimulate GH release through a distinct pathway that is partially additive with GHRH. Macimorelin and ghrelin itself also act on GHS-R1a .

The receptor selectivity matters. Ipamorelin is a relatively selective GHS-R1a agonist with little effect on cortisol, prolactin, or appetite at typical doses. GHRP-6 stimulates appetite and shows more cortisol effect. Hexarelin shows tachyphylaxis and a more pronounced cardiovascular signal at higher doses. MK-677 is orally available and has the longest circulating half-life of the family, making it qualitatively different from the injected peptides.

Approved products in this family

• Tesamorelin (Egrifta WR): FDA-approved for HIV-associated lipodystrophy in adults; demonstrably reduces visceral adipose tissue .
• Macimorelin (Macrilen): FDA-approved as a diagnostic test for adult growth hormone deficiency. Single oral dose, with serial GH sampling. Approved 2017 .
• Sermorelin (Geref): originally FDA-approved as a pediatric short-stature treatment, with the approved product later discontinued from the US market for commercial reasons; the historical approval record remains accessible through Drugs@FDA . Sermorelin in current US clinical use comes from compounding pharmacies, not as an FDA-approved product.
• Recombinant human growth hormone (somatropin, e.g., Genotropin, Norditropin, Humatrope, Skytrofa, Sogroya): FDA-approved for multiple indications including pediatric and adult growth hormone deficiency. These are not secretagogues; they are exogenous GH replacement.

MK-677 (ibutamoren), the longest human-trial dataset

MK-677 is the most studied compound in the family in terms of human exposure duration. The Nass et al. 2008 trial randomized 65 healthy older adults to 25 mg MK-677 oral or placebo for 12 months. MK-677 raised IGF-1 to levels typical of young adults and increased fat-free mass by approximately 1 kg compared with placebo. Fasting glucose rose modestly, with elevations in HbA1c also reported in some subgroups .

Adler et al. and earlier studies in older adults reported similar effects: IGF-1 elevation, lean-mass gain, and a tendency toward edema and insulin resistance. The Murphy et al. 2001 trial in adults with growth hormone deficiency reported similar findings . MK-677 was also studied in hip-fracture rehabilitation; the trial did not meet its functional endpoint despite IGF-1 increases.

MK-677 is not FDA-approved for any indication. It is widely sold as a research compound and is on the WADA Prohibited List under S2 peptide hormones, growth factors, related substances, and mimetics .

Tesamorelin and the visceral fat dataset

Tesamorelin is a stabilized GHRH analog approved for HIV-associated lipodystrophy. The pivotal trials randomized adults with HIV and excess visceral adipose tissue to tesamorelin 2 mg subcutaneous daily or placebo for 26 weeks. Visceral adipose tissue decreased by approximately 15 to 18 percent from baseline on tesamorelin, with concurrent decreases in waist circumference and triglycerides. IGF-1 rose into the upper-quartile range. The drug is dosed in the morning and is sensitive to pen-injector handling; current product is Egrifta WR (water-reconstitution-free) .

Off-label use of tesamorelin for general visceral adiposity outside HIV is not supported by FDA-approved labeling. The published trials in non-HIV populations are limited and do not replicate the labeled indication's safety and efficacy package.

How secretagogues differ from recombinant GH

Recombinant human GH (somatropin) provides exogenous GH directly. The pituitary feedback loop is bypassed; the somatostatin brake cannot reduce circulating drug levels. Adverse effects (edema, carpal tunnel syndrome, insulin resistance, intracranial hypertension) are dose-related and predictable. The labeled adult indications are growth hormone deficiency, AIDS-associated wasting, and short-bowel syndrome. Off-label use for healthy adults raises safety concerns documented in the FDA labeling .

GH secretagogues, by contrast, work through the somatotroph and preserve at least some of the pulsatile GH-release physiology and the somatostatin feedback brake. The trade-off is that the maximal GH elevation achievable is bounded by pituitary reserve, and the effect attenuates over time in some compounds (tachyphylaxis is documented for hexarelin and partially for GHRP-6). Effects on IGF-1 are real but smaller in magnitude than those achievable with rhGH at GH-replacement doses .

WADA, USADA, and doping status

WADA prohibits growth hormone, all GH secretagogues (including ipamorelin, MK-677, GHRP-2, GHRP-6, sermorelin, CJC-1295, tesamorelin), and growth factors at all times under section S2 of the WADA Prohibited List. The prohibition is class-based and explicit, including released GH and any compound that promotes GH release . USADA mirrors the WADA list for US athletes .

The doping classification is independent of FDA approval status. A compound being unapproved (or compounded only) does not exempt it from the WADA list, and an FDA-approved product like tesamorelin remains prohibited in elite competition.

What the evidence does not show

• GH secretagogues have not been shown to extend lifespan in any controlled human trial.
• GH secretagogues do not consistently reproduce the rhGH magnitude of effect on body composition outside the tesamorelin-HIV-lipodystrophy population.
• Compounded sermorelin, ipamorelin, CJC-1295, and MK-677 do not have published trials for general anti-aging, sleep quality, or body recomposition that meet trial-grade standards.
• Long-term cancer-incidence data on chronically elevated IGF-1 from secretagogue use are not available; mechanistic concerns remain.